Raul Santos Articles

Professor Santos discusses HAUSER-RCT

PCSK9 inhibition: impact on stroke

Prof Raul Santos, from the Heart Institute (InCor) University of Sao Paulo Medical School Hospital and the Hospital Israelita Albert Einstein, São Paulo, Brazil discusses the latest findings from FOURIER. Stroke brings a high burden of individual and family suffering, in addition to elevated health…

Professor Raul Santos (University of São Paulo, Brazil): Why was the mortality benefit in ODYSSEY Outcomes only evident after 1 year of follow-up?

Professor Raul Santos (University of São Paulo, Brazil): What are the key take home messages from ODYSSEY Outcomes?

Will ODYSSEY Outcomes change the management of ACS patients?

Evolocumab in lower extremity peripheral artery disease

Lower extremity peripheral artery disease (LEPAD) is associated with an elevated risk of atherosclerotic cardiovascular disease (ASCVD) and mortality1. Classically, risk factors for LEPAD are heavy smoking, diabetes and older age, although dyslipidaemia also predisposes to LEPAD, as shown by a recent study2. Furthermore, Pereira…

VIDEO: Prof Raul Santos: How can PCSK9 monoclonal antibody therapy be cost effective?

Prof Raul Santos: Do PCSK9 inhibitors have adverse effects on neurocognition

Prof Raul Santos: SPIRE trials with bococizumab

The data from the SPIRE programme, especially SPIRE-1 and SPIRE-2 the cardiovascular outcomes studies was also illuminating. PCSK9 Forum Editor Professor Raul Santos, one of the authors, gives his view.

Insights from Brazil: Raul Santos, InCor-University of Sao Paulo

The Healthcare Perspective in South America

SAFEHEART: Consider more than coronary complications in FH

The Spanish Familial Hypercholesterolaemia Cohort Study (SAFEHEART) has highlighted the prevalence and different distribution of atherosclerotic cardiovascular disease (ASCVD) in individuals with familial hypercholesterolaemia (FH, inherited high cholesterol). In particular, coronary artery disease and peripheral artery disease were more prevalent among those with FH than…

Why do we need a definition for severe forms of familial hypercholesterolemia?

Raul D. Santos MD, PhD on behalf of the International Atherosclerosis Society Panel on Severe Familial Hypercholesterolemia, discusses why this is critical to the best current use of PCSK9 inhibitors in clinical practice. Familial hypercholesterolemia (FH, inherited high cholesterol) is common in individuals who suffer…

EAS Consensus Panel on Paediatric FH

Dr Raul Santos discusses the EAS Consensus Panel statement on FH in children – Spanish Dr Raul Santos discusses the EAS Consensus Panel statement on FH in children – Portuguese

ODYSSEY FH and patient unmet needs

Less than 1% of people with familial hypercholesterolaemia (FH), the commonest genetic disorder in the world are diagnosed. As FH patients have significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) their consequent risk of cardiovascular death is greatly increased. Therefore, the results of the ODYSSEY…

Improving the management of the FH patient

Professor Raul Santos from Brazil says that the new therapies which inhibit PCSK9 to significantly reduce low density Lipoprotein Cholesterol (LDL-C) when given in addition to other cholesterol lowering drugs offer a very important advance in reducing cardiovascular risk in people with Familial Hypercholesterolemia (FH).

Missing FH: How can we improve FH referral and diagnosis?

Heterozygous familial hypercholesterolemia (FH) is neither a rare disease nor a sentence to a life full of complications and early death. Recent evidence shows that even when founder effects are taken into account, heterozygous FH affects around 1/200-300 people instead of the historical estimate of…